Retatrutide
GIP/GLP-1/Glucagon triple receptor agonist analog
A triple-agonist analog targeting GIP, GLP-1, and glucagon (GCGR) receptors simultaneously, representing an actively investigated frontier in metabolic research literature — cited research reports body-mass reductions up to ~29% from baseline in trial populations, the largest of the three GLP-1-family compounds in this catalogue.
What researchers are studying Retatrutide for.
Triple Incretin/Glucagon-Receptor Agonism
Body-Mass Reduction Research
Metabolic-Frontier Research
Proprietary triple-agonist sequence — see certificate of analysis
Concentration and unit math, worked out.
Worked example for a 10mg vial reconstituted with 3mL of bacteriostatic water, drawn on a U-100 insulin syringe. Use the calculator below for any other vial size or water volume.
| UNITS DRAWN | VOLUME | DELIVERS |
|---|---|---|
| 5 units | 0.05 mL | 167 mcg |
| 10 units | 0.10 mL | 333 mcg |
| 20 units | 0.20 mL | 667 mcg |
| 30 units | 0.30 mL | 1000 mcg |
| 50 units | 0.50 mL | 1667 mcg |
Run your own numbers.
Pre-filled with a 30-day starting point — one vial, dosed once daily for 30 days. Adjust any field to match your own protocol.
RESULTS
Educational reference tool only — not medical advice. Reconstitution and dosing decisions for any research protocol should be reviewed with a qualified professional. Figures assume uniform mixing and standard syringe calibration; always verify against your own protocol.